Company intelligence / Profile preview

Noventia Pharma

Lausanne, Switzerland

Ownership: Private
Employees: ~31
Development stage: Other

Overview

Noventia Pharma has commercialized Ceplene (histamine dihydrochloride) for maintenance treatment of AML in patients under 60 years in first complete remission[1]. The company is actively researching treatments for ultra-rare diseases including Lafora disease and Pompe disease through its CNS focus, and for rare gastrointestinal conditions through its subsidiary Napo Therapeutics[2].

Therapeutic areas: OncologyNeurologyRare DiseasesGastroenterology
Modalities: Small molecule
Industry: Biotech

Partnerships

Military Pharma (exclusive agreement for rare diseases in Southern Europe)DELBERT Laboratories (acquired European marketing authorization for Ceplene in September 2022)

Beyond the preview

Go deeper on Noventia Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Noventia Pharma.

Explore the full profile